The possible of immunotherapy for COVID-19: A systematic review.
Identifieur interne : 000045 ( PubMed/Checkpoint ); précédent : 000044; suivant : 000046The possible of immunotherapy for COVID-19: A systematic review.
Auteurs : Akram Aminjafari [Iran] ; Sorayya Ghasemi [Iran]Source :
- International immunopharmacology [ 1878-1705 ] ; 2020.
Abstract
The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.
DOI: 10.1016/j.intimp.2020.106455
PubMed: 32272396
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32272396Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The possible of immunotherapy for COVID-19: A systematic review.</title>
<author><name sortKey="Aminjafari, Akram" sort="Aminjafari, Akram" uniqKey="Aminjafari A" first="Akram" last="Aminjafari">Akram Aminjafari</name>
<affiliation wicri:level="1"><nlm:affiliation>Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord</wicri:regionArea>
<wicri:noRegion>Shahrekord</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghasemi, Sorayya" sort="Ghasemi, Sorayya" uniqKey="Ghasemi S" first="Sorayya" last="Ghasemi">Sorayya Ghasemi</name>
<affiliation wicri:level="1"><nlm:affiliation>Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address: sorayya.ghasemi@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord</wicri:regionArea>
<wicri:noRegion>Shahrekord</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32272396</idno>
<idno type="pmid">32272396</idno>
<idno type="doi">10.1016/j.intimp.2020.106455</idno>
<idno type="wicri:Area/PubMed/Corpus">000057</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000057</idno>
<idno type="wicri:Area/PubMed/Curation">000057</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000057</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000045</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000045</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The possible of immunotherapy for COVID-19: A systematic review.</title>
<author><name sortKey="Aminjafari, Akram" sort="Aminjafari, Akram" uniqKey="Aminjafari A" first="Akram" last="Aminjafari">Akram Aminjafari</name>
<affiliation wicri:level="1"><nlm:affiliation>Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord</wicri:regionArea>
<wicri:noRegion>Shahrekord</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ghasemi, Sorayya" sort="Ghasemi, Sorayya" uniqKey="Ghasemi S" first="Sorayya" last="Ghasemi">Sorayya Ghasemi</name>
<affiliation wicri:level="1"><nlm:affiliation>Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address: sorayya.ghasemi@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord</wicri:regionArea>
<wicri:noRegion>Shahrekord</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">International immunopharmacology</title>
<idno type="eISSN">1878-1705</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32272396</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>83</Volume>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>International immunopharmacology</Title>
<ISOAbbreviation>Int. Immunopharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The possible of immunotherapy for COVID-19: A systematic review.</ArticleTitle>
<Pagination><MedlinePgn>106455</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1567-5769(20)30912-7</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.106455</ELocationID>
<Abstract><AbstractText>The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>AminJafari</LastName>
<ForeName>Akram</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Cellular and Molecular Research Center, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ghasemi</LastName>
<ForeName>Sorayya</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address: sorayya.ghasemi@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Int Immunopharmacol</MedlineTA>
<NlmUniqueID>100965259</NlmUniqueID>
<ISSNLinking>1567-5769</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019-nCoV</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Immunotherapy</Keyword>
<Keyword MajorTopicYN="N">Interleukin</Keyword>
<Keyword MajorTopicYN="N">Monoclonal antibody</Keyword>
<Keyword MajorTopicYN="N">Vaccine</Keyword>
</KeywordList>
<CoiStatement>Declaration of Competing of Interest There is no potential conflict of interest for authors to disclose.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32272396</ArticleId>
<ArticleId IdType="pii">S1567-5769(20)30912-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.intimp.2020.106455</ArticleId>
<ArticleId IdType="pmc">PMC7128194</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Iran</li>
</country>
</list>
<tree><country name="Iran"><noRegion><name sortKey="Aminjafari, Akram" sort="Aminjafari, Akram" uniqKey="Aminjafari A" first="Akram" last="Aminjafari">Akram Aminjafari</name>
</noRegion>
<name sortKey="Ghasemi, Sorayya" sort="Ghasemi, Sorayya" uniqKey="Ghasemi S" first="Sorayya" last="Ghasemi">Sorayya Ghasemi</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:32272396 |texte= The possible of immunotherapy for COVID-19: A systematic review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32272396" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |